DKK1 and melanoma: Next, we administered the DKK1-neutralizing monoclonal antibody mDKN01, previously validated for its anti-tumor effects in melanoma, gastric, and gynecologic mouse tumor models24,26,30–32 and currently under investigation in clinical trials for gastric and endometrial cancers (NCT04363801, NCT05761951, NCT04681248).